Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.95 · Expires 2035-06-12 | Direct | 38,513 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 38,513 · Balance 38,513 F1: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 16, 2025 20:14 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 38,513 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0000950170-25-086737 · ownership.xml · derivative · entry 1 Ryan David P. · CIK 0001951490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,513 Underlying: Common Stock · 38,513 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option represents a right to purchase a total of 38,513 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 12, 2026 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 23:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 15,806 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0000950170-24-078675 · ownership.xml · derivative · entry 1 Ryan David P. · CIK 0001951490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,806 Underlying: Common Stock · 15,806 shares Expires 2034-06-26 F1 · derivative.exercise_date: The option represents a right to purchase a total of 15,806 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 26, 2025 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 20:36 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 26,150 | $0.00 Strike: $13.26 | $0.00 |
DisclosureSEC source: 0000899243-22-034765 · doc4.xml · derivative · entry 1 Ryan David P. · CIK 0001951490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,150 Underlying: Common Stock · 26,150 shares Expires 2032-10-31 F1 · derivative.exercise_date: The option represents a right to purchase a total of 26,150 shares of the Issuer's Common Stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.